Exclusive: Frontiers Health - Day one coverage Views & Analysis Adam Jeffery 17 November, 2016 data Bookmark this
News FDA gives the go-ahead to restart Elevidys shipments Sarepta has restarted distribution of its Duchenne muscular dystrophy gene therapy Elevidys, but only for patients who can walk.
R&D From data to impact: How real-world evidence will transform ... Real-world evidence (RWE) has moved from the periphery to the centre of how healthcare decisions are made.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
R&D Deep Dive: Research and Development 2025 Every breakthrough in medicine, every new treatment that changes lives, starts with research.
R&D Life Sciences Industry Report - Biologics and Generics The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.
Oncology Following science to fruition, putting patients first: An AS... At ASCO25, AstraZeneca presented late-breaking data from the DESTINY-Breast09 Phase III trial. Alison Dziarmaga discussed the data with pharmaphorum.
Oncology Life Sciences Industry Report - Oncology Developments in the oncology space in 2024 brought hope to both industry and patients.
R&D Partner Content Revolutionising Clinical Trials: Evolution Summit 2025 Retur... Marcus Evans is proud to announce the Evolution Summit September 2025, an exclusive, invitation-only event bringing together leading clinical trial executives, innovative suppliers
R&D Partner Content Welcome to the 3rd Spatial Biology for Drug Development Summ... Transforming Research & Development with Faster, More Precise Spatial Insights
News FDA gives the go-ahead to restart Elevidys shipments Sarepta has restarted distribution of its Duchenne muscular dystrophy gene therapy Elevidys, but only for patients who can walk.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face